FOR IMMEDIATE RELEASE – September 16, 2022
CPR Therapeutics Inc. receives National Institutes of Health Direct-To-Phase II Small Business Innovation Research Award for further development of its breakthrough technology for cardiopulmonary resuscitation
CPR Therapeutics Inc. (CPR-T), a Vermont-based medical device start-up company, announced today that it has received a $1.6M National Institutes of Health (NIH) National Heart Lung and Blood Institute (NHLBI) Direct-To-Phase II Small Business Innovation Research Award for its project “A MULTIMODAL INTEGRATED SYSTEM FOR IMPROVED CARDIOPULMONARY RESUSCITATION.” The project will be conducted in collaboration with The Johns Hopkins Hospital in Baltimore, MD.
CPR Therapeutics is developing multimodal cardiopulmonary resuscitation (CPR), a more effective form of automated mechanical CPR. Sudden cardiac arrest is the leading cause of death in western countries and there are currently no devices more effective than manual chest compressions. Intact survival after sudden cardiac arrest is below 10% in most communities.
Norman Paradis MD, CPR Therapeutic’s Founder and CEO said “We are tremendously excited to have received this level of support from one of the world’s most prestigious medical research institutions. Direct-to-Phase II means that the NIH-NHLBI reviewers agree that we have made significant progress already.”
Henry Halperin MD, the company’s Chief Scientific Officer and a Professor of Cardiology and Biomedical Engineering at Johns Hopkins said “this level of support should be sufficient for us to complete research and development of our first generation multimodal CPR device. The NHLBI review process is rigorous, so I can’t think of a better validation of our underlying science, our efforts so far, and the current development and business plans.”
The NIH support will accelerate the Company’s preclinical R&D and device prototyping. Dr. Paradis further concluded “At the end of these efforts we should have our first clinical system and be ready to submit it for FDA clearance. Our whole team could not be more excited.”
CPR Therapeutics Inc.
CPR Therapeutics Inc. is a medical device start-up company developing the first advanced technology automated CPR system that integrates and synchronizes multiple technological innovations into a single system that can be easily applied under emergency conditions. The Company believes that this technology will, for the first time, demonstrate clinically significant improvements in intact survival after sudden death. The largest killer in Western Countries. Info@CPRTherapeutics.com
DISCLAIMER:The information provided pertaining to CPR Therapeutics Inc. (“CPR-T” or the “Company”), its business assets, strategy and operations is for general informational purposes only and is not a formal offer to sell or a solicitation of an offer to buy any securities, options, futures, or other derivatives related to securities in any jurisdiction and its content is not prescribed by securities laws. Information contained in this presentation should not be relied upon as advice to buy or sell or hold such securities or as an offer to sell such securities. This presentation does not take into account nor does it provide any tax, legal or investment advice or opinion regarding the specific investment objectives or financial situation of any person. While the information in this presentation is believed to be accurate and reliable, CPR-T and its agents, advisors, directors, officers, employees and shareholders make no representation or warranties, expressed or implied, as to the accuracy of such information and CPR-T expressly disclaims any and all liability that may be based on such information or errors or omissions thereof. CPR-T reserves the right to amend or replace the information contained herein, in part or entirely, at any time, and undertakes no obligation to provide the recipient with access to the amended information or to notify the recipient thereof